This has led to the identification of a more effective combination therapy in which a PRKDC inhibitor greatly enhances the efficacy of doxorubicin in ABC-Myc mice and human hepatoblastoma xenograft models. This evidence concerns the gene PRKDC and hepatoblastoma.